BioXcel Therapeutics Inc (BTAI) - Total Liabilities
Based on the latest financial reports, BioXcel Therapeutics Inc (BTAI) has total liabilities worth $139.57 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of BioXcel Therapeutics Inc to track the company's year-over-year net asset growth rate.
BioXcel Therapeutics Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how BioXcel Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data.
BioXcel Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of BioXcel Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
iBio, Inc. Common Stock
NYSE MKT:IBIO
|
USA | $8.12 Million |
|
Odessa Minerals Ltd
AU:ODE
|
Australia | AU$165.72K |
|
Ion Video Ltd
AU:IOV
|
Australia | AU$2.81 Million |
|
Mestron Holdings
KLSE:0207
|
Malaysia | RM62.94 Million |
|
Higgstec
TWO:5220
|
Taiwan | NT$400.56 Million |
|
Helios Towers Plc
LSE:HTWS
|
UK | GBX2.29 Billion |
|
JFB Construction Holdings Class A Common Stock
NASDAQ:JFB
|
USA | $2.31 Million |
|
Change Financial Ltd
AU:CCA
|
Australia | AU$9.24 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down BioXcel Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of BioXcel Therapeutics Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioXcel Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioXcel Therapeutics Inc (2015–2025)
The table below shows the annual total liabilities of BioXcel Therapeutics Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $140.38 Million | +6.80% |
| 2024-12-31 | $131.44 Million | +0.94% |
| 2023-12-31 | $130.21 Million | +0.88% |
| 2022-12-31 | $129.08 Million | +626.30% |
| 2021-12-31 | $17.77 Million | +34.23% |
| 2020-12-31 | $13.24 Million | +39.41% |
| 2019-12-31 | $9.50 Million | +103.80% |
| 2018-12-31 | $4.66 Million | +99.40% |
| 2017-12-31 | $2.34 Million | +606.04% |
| 2016-12-31 | $331.00K | +89.14% |
| 2015-12-31 | $175.00K | -- |
About BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more